Post-menopausal osteoporosis, a global public health problem, has for decades been attributed solely to declining estrogen levels, and although follicle stimulating hormone (FSH) levels rise sharply in parallel, a direct effect of FSH on the skeleton has never been explored. The only ascribed function of FSH is ovarian estrogen secretion. We speculate that, in addition to declining estrogen, FSH drives the decreases in bone mass during the early menopause by stimulating the osteoclast, the cell that resorbs bone. Mice devoid of FSH or its receptor do not display hyper-resorption or bone loss despite being severely hypogonadal. That FSH is pro-resorptive is supported by in vitro evidence for a G-protein coupled FSH receptor (FSHR) on the osteoclast. FSH also enhances the release of the osteoclastogenic cytokine TNFa from osteoclast precursors, and additionally, promotes osteoclast survival. The hypothesis emerging from our study, supported by the tight correlations between bone mass and serum FSH in humans, is that circulating FSH directly stimulates osteoclastic bone resorption. We will therefore investigate in Specific Aim 1 whether FSH causes bone loss in vivo independently of lowered estrogen. For this, we will administer or over-express FSH in mice lacking the two estrogen receptors, ER??-/-, as well as GnRH-deficient hpg mice. We will also examine whether selective FSHR deletion in the osteoclast will prevent ovariectomy-induced bone loss, and whether transgenic reconstitution of the FSHR in FSHR-/- osteoclasts will restore resorptive activity.
In Specific Aim 2 we determine the mechanism of the FSH effect. We will first study the mechanism of FSH-induced TNFa expression, and then, using TNFa-/- mice, elucidate if the entire effect of FSH is TNFa-dependent. Finally, using Akt-deficient cells, we will also determine whether the pro-survival action of FSH is Akt-mediated. If FSH is proven to be pro-resorptive in vivo, we envisage attenuating FSH in humans to a skeletal advantage without compromising ovarian function, for example by a monoclonal antibody. The latter premise arises from our observation that FSH haploinsufficiency in mice increases bone mass, while sparing the ovaries. The significance of this work thus lies not only in our challenging an archetypal paradigm, estrogen deficiency, as being the full explanation for menopausal bone loss, but also in establishing that pituitary hormones, such as FSH, act beyond traditional target endocrine organs.
|Colaianni, Graziana; Sun, Li; Zaidi, Mone et al. (2014) Oxytocin and bone. Am J Physiol Regul Integr Comp Physiol 307:R970-7|
|New, Maria I; Tong, Yu K; Yuen, Tony et al. (2014) Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J Clin Endocrinol Metab 99:E1022-30|
|Mistry, Pramod K; Liu, Jun; Sun, Li et al. (2014) Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease. Proc Natl Acad Sci U S A 111:4934-9|
|Colaianni, G; Tamma, R; Di Benedetto, A et al. (2014) The oxytocin-bone axis. J Neuroendocrinol 26:53-7|
|Iqbal, Jameel; Sun, Li; Cao, Jay et al. (2013) Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc Natl Acad Sci U S A 110:11115-20|
|Arnason, Barry G; Berkovich, Regina; Catania, Anna et al. (2013) Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler 19:130-6|
|Sun, Li; Zhu, Ling-Ling; Lu, Ping et al. (2013) Genetic confirmation for a central role for TNF* in the direct action of thyroid stimulating hormone on the skeleton. Proc Natl Acad Sci U S A 110:9891-6|
|Qin, Weiping; Sun, Li; Cao, Jay et al. (2013) The central nervous system (CNS)-independent anti-bone-resorptive activity of muscle contraction and the underlying molecular and cellular signatures. J Biol Chem 288:13511-21|
|New, Maria I; Abraham, Moolamannil; Gonzalez, Brian et al. (2013) Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci U S A 110:2611-6|
|Cuscito, Concetta; Colaianni, Graziana; Tamma, Roberto et al. (2011) Adrenergic stimulation decreases osteoblast oxytocin synthesis. Ann N Y Acad Sci 1237:53-7|
Showing the most recent 10 out of 44 publications